

Additional File 3: List of coded sources and issues, by source

<u>Year</u>	<u>Author(s)</u>	<u>Title</u>	<u>Ethical and legal Issue Mentioned in Reference</u>						
			Harm Exposure and Risks to Health	Consent to Nanomedical Research	Privacy	Access to Nanomedicine	Classification of Nanomedical Products	Precautionary Principle	Other Issues
<b>2007</b>	Jotterand F	Nanomedicine: how it could reshape clinical practice							<b>X</b>
<b>2007</b>	Evans D	Ethics, nanotechnology and health	<b>X</b>	<b>X</b>	<b>X</b>	<b>X</b>			<b>X</b>
<b>2007</b>	Resnik DB, Tinkle SS	Ethics in nanomedicine. Nanomedicine		<b>X</b>		<b>X</b>			
<b>2007</b>	Toumey C	Privacy in the shadow of nanotechnology			<b>X</b>				
<b>2008</b>	Brownsword R	Regulating nanomedicine – the smallest of our concerns?						<b>X</b>	
<b>2008</b>	Karlsson HL, Cronholm P, Gustafsson J, Möller L	Copper oxide nanoparticles are highly toxic: a comparison between metal oxide nanoparticles and carbon nanotubes	<b>X</b>						
<b>2008</b>	Marchant GE, Sylvester DJ, Abbott KW	Risk management principles for nanotechnology. Nanoethics						<b>X</b>	
<b>2008</b>	Schummer J, Pariotti E	Regulating nanotechnologies: Risk management models and nanomedicine					<b>X</b>		
<b>2009</b>	McHale JV	Nanomedicine and the EU: Some legal, ethical					<b>X</b>		

Additional File 3: List of coded sources and issues, by source

<u>Year</u>	<u>Author(s)</u>	<u>Title</u>	<u>Ethical and legal Issue Mentioned in Reference</u>						
			Harm Exposure and Risks to Health	Consent to Nanomedical Research	Privacy	Access to Nanomedicine	Classification of Nanomedical Products	Precautionary Principle	Other Issues
		and regulatory challenges							
<b>2009</b>	Meetoo D	Nanotechnology: is there a need for ethical principles?				<b>X</b>			
<b>2009</b>	Stebbing M	Avoiding the trust deficit: Public engagement, values, the precautionary principle and the future of nanotechnology						<b>X</b>	
<b>2010</b>	Marchant GE, Sylvester DJ, Abbott KW, Danforth TL	International harmonization of regulation of nanomedicine	<b>X</b>						
<b>2011</b>	Bawa R	Regulating nanomedicine – can the FDA handle it?	<b>X</b>				<b>X</b>		
<b>2011</b>	Könczöl M, Ebeling S, Goldenberg E, Treude F, Gminski R, Gieré, et al	Cytotoxicity and genotoxicity of size-fractionated iron oxide (magnetite) in A549 human lung epithelial cells: Role of ROS, JNK, and NF-κB	<b>X</b>						
<b>2011</b>	Nel A, Grainger D, Alvarez PJ, Badesha	Nanotechnology environmental, health, and safety issues	<b>X</b>						

Additional File 3: List of coded sources and issues, by source

<u>Year</u>	<u>Author(s)</u>	<u>Title</u>	<u>Ethical and legal Issue Mentioned in Reference</u>						
			Harm Exposure and Risks to Health	Consent to Nanomedical Research	Privacy	Access to Nanomedicine	Classification of Nanomedical Products	Precautionary Principle	Other Issues
<b>2012</b>	Fisher E, Boenink M, van der Burg S, Woodbury N	Responsible healthcare innovation: anticipatory governance of nanodiagnostics for theranostics medicine			<b>X</b>	<b>X</b>			
<b>2012</b>	Glenn LM, Boyce JS	Regenerative nanomedicine: Ethical, legal, and social issues					<b>X</b>		
<b>2014</b>	Trisolino A	Nanomedicine: Building a bridge between science and law	<b>X</b>				<b>X</b>	<b>X</b>	
<b>2014</b>	Lu X, Zhu T, Chen C, Liu Y	Right or left: the role of nanoparticles in pulmonary diseases	<b>X</b>						
<b>2015</b>	Bowman DM, Gatof J	Reviewing the regulatory barriers for nanomedicine: global questions and challenges					<b>X</b>		
<b>2016</b>	Schroeder D, Dalton-Brown S, Schrempf B, Kaplan D	Responsible, inclusive innovation and the nano-divide				<b>X</b>	<b>X</b>		
<b>2016</b>	Atalla K, Chaudhary A, Eshaghian-Wilner MM, Gupta A, Mehta R, Nayak A, et al.	Ethical, privacy, and intellectual property issues in nanomedicine	<b>X</b>	<b>X</b>					
<b>2016</b>	Marchant GE	What is a nanomaterial?					<b>X</b>		

Additional File 3: List of coded sources and issues, by source

<u>Year</u>	<u>Author(s)</u>	<u>Title</u>	<u>Ethical and legal Issue Mentioned in Reference</u>						
			Harm Exposure and Risks to Health	Consent to Nanomedical Research	Privacy	Access to Nanomedicine	Classification of Nanomedical Products	Precautionary Principle	Other Issues
<b>2019</b>	Paradise J	Regulating nanomedicine at the food and drug administration					<b>X</b>		
<b>2019</b>	Peng F, Setyawati MI, Tee JK, Ding X, Wang DJ, Nga ME et al.	Nanoparticles promote in vivo breast cancer cell intravasation and extravasation by inducing endothelial leakiness	<b>X</b>						
<b>2020</b>	Foulkes R, Man E, Thind J, Yeung S, Joy A, Hoskins C	The regulation of nanomaterials and nanomedicines for clinical application: current and future perspectives					<b>X</b>		
<b>2021</b>	Gutierrez E	Privacy implications of nanotechnology			<b>X</b>				
<b>Total</b>	27		10	3	4	5	10	4	2